Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B

(2011) C. Negrier et al.   BLOOD

A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing

(2011) S. BJÖRKMAN   HAEMOPHILIA

A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine®, a high-purity factor IX concentrate, in patients with severe haemophilia B

(2011) T. LISSITCHKOV et al.   HAEMOPHILIA

Insights from factor IX activation studies with chromogenic assays: implications of disparate product results

(2010) T. W. BARROWCLIFFE   HAEMOPHILIA

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia

(2010) P. W. COLLINS et al.   HAEMOPHILIA

Factor IX pharmacokinetics: differences between plasma-derived and recombinant products and the clinical and economic implications: a meeting report

(2008) M. MORFINI et al.   HAEMOPHILIA